LV13250B - A composition for treating neurocerebrovascular disorders - Google Patents

A composition for treating neurocerebrovascular disorders Download PDF

Info

Publication number
LV13250B
LV13250B LVP-04-78A LV040078A LV13250B LV 13250 B LV13250 B LV 13250B LV 040078 A LV040078 A LV 040078A LV 13250 B LV13250 B LV 13250B
Authority
LV
Latvia
Prior art keywords
present
another embodiment
composition
fraction
style
Prior art date
Application number
LVP-04-78A
Other languages
English (en)
Latvian (lv)
Inventor
Madhur Ray
Raghwendra Pal
Satyawan Singh
Nandoo Mal Khanna
Original Assignee
Council Scient Ind Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Scient Ind Res filed Critical Council Scient Ind Res
Publication of LV13250B publication Critical patent/LV13250B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
LVP-04-78A 2001-12-14 2004-07-13 A composition for treating neurocerebrovascular disorders LV13250B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34016501P 2001-12-14 2001-12-14

Publications (1)

Publication Number Publication Date
LV13250B true LV13250B (en) 2006-02-20

Family

ID=23332163

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-04-78A LV13250B (en) 2001-12-14 2004-07-13 A composition for treating neurocerebrovascular disorders

Country Status (19)

Country Link
US (2) US20060051438A1 (fr)
EP (1) EP1453528B1 (fr)
JP (1) JP4695839B2 (fr)
KR (1) KR101001815B1 (fr)
CN (1) CN100528149C (fr)
AU (2) AU2002348802A1 (fr)
BR (1) BR0214962A (fr)
CA (1) CA2473874C (fr)
DE (1) DE60233069D1 (fr)
EA (1) EA007067B1 (fr)
EE (1) EE05374B1 (fr)
GE (1) GEP20084442B (fr)
LT (1) LT5284B (fr)
LV (1) LV13250B (fr)
MX (1) MXPA04005680A (fr)
NO (1) NO332066B1 (fr)
UA (1) UA82057C2 (fr)
WO (1) WO2003051380A2 (fr)
ZA (1) ZA200404648B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115366A1 (fr) * 2004-05-31 2005-12-08 Kaneka Corporation Agent pour prévenir/améliorer les maladies liées au mode de vie contenant un composant d'huile essentielle de curcuma
JPWO2006118079A1 (ja) * 2005-04-28 2008-12-18 新 山崎 皮膚の老化防止剤
US10286027B2 (en) 2005-05-30 2019-05-14 Arjuna Natural Extracts, Ltd. Sustained release formulations of curcuminoids and method of preparation thereof
US7883728B2 (en) 2005-05-30 2011-02-08 Arjuna Natural Extracts, Ltd. Composition to enhance the bioavailability of curcumin
US9492402B2 (en) 2005-05-30 2016-11-15 Benny Antony Formulation of curcuminoids with enhanced bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin and method of preparation and uses thereof
US8859020B2 (en) 2005-05-30 2014-10-14 Benny Antony Treatment of alzheimer's with a curcuminoid mixture and essential oil of turmeric having 45% Ar-turmerone
PL1890546T3 (pl) * 2005-05-30 2019-04-30 Benny Antony Sposób poprawiania biodostępności kurkuminy
US10543277B2 (en) 2005-05-30 2020-01-28 Arjuna Natural Private Limited Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof
JP4980626B2 (ja) * 2006-02-28 2012-07-18 ポーラ化成工業株式会社 プラスミノーゲンアクチベーターインヒビターｉ阻害剤及びそれを配合してなる食品組成物
JP5207341B2 (ja) * 2006-10-26 2013-06-12 独立行政法人産業技術総合研究所 炎症性サイトカイン産生抑制剤
MX2010003726A (es) 2007-10-03 2010-09-14 Sabell Corp Composiciones herbarias y metodos de tratamiento de trastornos hepaticos.
WO2010099985A2 (fr) * 2009-03-05 2010-09-10 Keygene N.V. Substances volatiles végétales à base de r-curcumène
CN102595884B (zh) 2009-07-31 2014-12-03 考格尼申治疗股份有限公司 认知衰退的抑制剂
JP5764288B2 (ja) 2009-09-24 2015-08-19 ハウス食品グループ本社株式会社 ウコン抽出物とガジュツ抽出物とを含有する組成物
JP5578822B2 (ja) * 2009-09-25 2014-08-27 株式会社ピカソ美化学研究所 アセチルコリンエステラーゼ阻害剤
JP2014511373A (ja) 2011-02-02 2014-05-15 コグニション セラピューティクス インク． ウコン油から単離された化合物およびその使用方法
EP2690969B1 (fr) 2011-03-29 2018-10-03 Council of Scientific & Industrial Research Procédé de modification d'huile essentielle de curcuma aromatica
GB201111319D0 (en) 2011-07-04 2011-08-17 Univ Leuven Kath Anticonvulsant activity of tumeric oil and bisabolene sesquiterpenoids of curcuma longa
KR101832283B1 (ko) * 2012-01-13 2018-02-26 주식회사 엘지생활건강 피부 주름 개선 및 탄력 증진용 조성물
CN102697757B (zh) * 2012-05-18 2014-06-04 广州军区广州总医院 对羟基苄叉丙酮在制备预防和/或治疗脑病药物中的应用
JP2014201528A (ja) * 2013-04-02 2014-10-27 クラシエ製薬株式会社 抗酸化剤
ES2721001T3 (es) 2014-01-31 2019-07-26 Cognition Therapeutics Inc Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa
CN104840451B (zh) * 2014-09-23 2017-04-05 桂林八加一药业股份有限公司 一种用于治疗冠心病、高脂血症的中药有效部位、制备方法及从中分离有效成分的方法
CN105738546B (zh) * 2014-12-12 2020-01-21 桂林八加一药业股份有限公司 毛郁金药材指纹图谱的建立方法及其指纹图谱
CN105055449B (zh) * 2015-07-27 2019-08-09 中国科学院西北高原生物研究所 一种具有抗炎镇痛活性的塞隆骨提取物、制备方法及中药制剂
CN106491997A (zh) * 2016-12-29 2017-03-15 王明金 一种抗精神障碍的中药组合物及其制备方法
CN106511784A (zh) * 2016-12-29 2017-03-22 王明金 一种治疗精神疾病的中药组合物及其制备方法
CN106491996A (zh) * 2016-12-29 2017-03-15 王明金 一种治疗狂躁症的中药组合物及其制备方法
CN106492137A (zh) * 2016-12-29 2017-03-15 王明金 一种治疗抑郁症的中药组合物及其制备方法
US20200062684A1 (en) * 2017-05-12 2020-02-27 House Wellness Foods Corporation Anti-Inflammatory Composition
KR102614814B1 (ko) 2017-05-15 2023-12-20 카그니션 테라퓨틱스, 인코퍼레이티드 신경변성 질환 치료용 조성물
US10391138B2 (en) * 2017-07-11 2019-08-27 Muniyal Ayurvedic Research Centre Multidimensional approach for Cancer treatment
CN108498755B (zh) 2018-04-17 2021-04-09 贾洪章 治疗心脑血管疾病的中药组合物及其制备方法和用途
US20210267914A1 (en) * 2018-06-29 2021-09-02 House Wellness Foods Corporation A Composition for Treatment, Prevention, or Amelioration of Alzheimer's Disease, a Composition for Suppression of Brain Nerve Cell Death, a Composition for Suppression of Microglia Activation Induced by Amyloid Beta Peptide, and a Composition for Suppression of PGE2, TNF-alpha, or IL-1beta Production Induced by Amyloid Beta Peptide
CN111617060A (zh) * 2020-05-29 2020-09-04 广东工业大学 吉马酮的应用
CN111617059B (zh) * 2020-05-29 2023-07-25 广东工业大学 莪术二酮的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU83350A1 (fr) 1981-05-08 1983-03-24 Oreal Composition destinee au traitement des fibres keratiniques a base de polymere cationique et de polymere anionique a groupements vinylsulfoniques et procede de traitement la mettant en oeuvre
IN162441B (fr) 1984-12-26 1988-05-28 Council Scient Ind Res
US4842859A (en) * 1986-09-08 1989-06-27 Yaguang Liu Pharmaceutical compositions for reducing hyperlipidemia and platelet-aggregation
US5120538A (en) * 1990-02-05 1992-06-09 Pt Darya-Varia Laboratoria Combinations of compounds isolated from curcuma spp as anti-inflammatory agents
US5863938A (en) * 1991-03-01 1999-01-26 Warner Lambert Company Antibacterial-wound healing compositions and methods for preparing and using same
CN1100321A (zh) * 1994-03-27 1995-03-22 叶启智 灵猫香或其复方药用针剂
AU2300001A (en) * 1999-10-22 2001-05-08 Board Of Trustees Of The University Of Illinois, The Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
DE10029770A1 (de) * 2000-06-16 2001-12-20 Transmit Technologietransfer Verwendung von Curcuminen zur Behandlung von soliden Tumoren,insbesondere von Hirntumoren
JP2002030081A (ja) * 2000-07-13 2002-01-29 Shiseido Co Ltd ジアリールヘプタノイド誘導体及びマトリックスメタロプロテアーゼ活性阻害剤
KR20020073847A (ko) * 2001-03-16 2002-09-28 주식회사 바이오시너젠 쿠르쿠민 또는 울금 추출물을 포함하는 치매 예방 및치료용 조성물

Also Published As

Publication number Publication date
EP1453528A2 (fr) 2004-09-08
WO2003051380A2 (fr) 2003-06-26
MXPA04005680A (es) 2004-10-15
US20100093870A1 (en) 2010-04-15
AU2009212969A1 (en) 2009-10-01
EE200400097A (et) 2004-10-15
AU2009212969B2 (en) 2011-06-02
GEP20084442B (en) 2008-08-10
JP2005516930A (ja) 2005-06-09
EA007067B1 (ru) 2006-06-30
EE05374B1 (et) 2011-02-15
LT5284B (lt) 2005-11-25
US20060051438A1 (en) 2006-03-09
CN1615144A (zh) 2005-05-11
EA200400807A1 (ru) 2004-12-30
CA2473874C (fr) 2011-11-22
NO332066B1 (no) 2012-06-18
BR0214962A (pt) 2004-12-14
UA82057C2 (en) 2008-03-11
KR101001815B1 (ko) 2010-12-15
JP4695839B2 (ja) 2011-06-08
LT2004060A (en) 2005-06-27
EP1453528B1 (fr) 2009-07-22
CN100528149C (zh) 2009-08-19
NO20043000L (no) 2004-07-13
CA2473874A1 (fr) 2003-06-26
KR20040073478A (ko) 2004-08-19
ZA200404648B (en) 2005-11-30
WO2003051380A3 (fr) 2004-06-17
DE60233069D1 (de) 2009-09-03
AU2002348802A1 (en) 2003-06-30

Similar Documents

Publication Publication Date Title
CA2473874C (fr) Composition pour le traitement des troubles neurocerebrovasculaires
Liczbiński et al. Molecular mechanism of curcumin action in signaling pathways: Review of the latest research
US6991814B2 (en) Herbal medicaments for the treatment of neurocerebrovascular disorders
Birdane et al. Anti-inflammatory and antinociceptive effects of Melissa officinalis L. in rodents
AU2008289713B2 (en) Fraction of Melissa leaf extract having angiogenesis and MMP inhibitory activities, and composition comprising the same
JP2013526487A (ja) リンゴの皮由来のフェノール組成物およびその使用
KR101869185B1 (ko) 혈액학적 장애의 치료에 사용하기 위한 glyt1 억제제
Yang et al. A review on α-mangostin as a potential multi-target-directed ligand for Alzheimer's disease
KR101285234B1 (ko) 백미 추출물을 포함하는 관절염 예방 및 치료용 조성물
Ibrahim et al. Leaves extract of Muntingia calabura protects against gastric ulcer induced by ethanol in Sprague-dawley rats
AU2021204271A1 (en) Synergistic composition for osteoarthritis
KR100494482B1 (ko) 간세포 보호 효과를 갖는 황칠 추출물, 황칠 분획물 및이들을 함유한 약학 조성물
JP4980626B2 (ja) プラスミノーゲンアクチベーターインヒビターｉ阻害剤及びそれを配合してなる食品組成物
KR20040097112A (ko) 간세포 보호 효과를 갖는 황칠 추출물, 황칠 분획물을유효성분으로 하는 건강 보조 식품
KR101782962B1 (ko) 백혈병 치료용 조성물 및 몰약 추출물의 제조방법
WO2009141645A1 (fr) Thérapie anticancéreuse
KR102069125B1 (ko) 강황 추출물을 포함하는 간손상 예방 및 치료용 약학 조성물
WO2020213616A1 (fr) Composition servant à prévenir et/ou à traiter la maladie d'alzheimer et/ou la démence d'alzheimer, et composition servant à réduire la neurotoxicité de l'oligomère bêta-amyloïde
KR100491439B1 (ko) 혈소판 응집 억제활성이 우수한 필발 나무 추출물 및 이의용도
Chopade et al. Evaluation of membrane stabilizing and inhibition of protein denaturation activity of Phyllanthus fraternus Webster
Maurya et al. PHYTOCHEMICAL AND PHARMACOLOGICAL INVESTIGATION OF OCIMUM SANCTUM MEDICINAL PLANTS FOR THE TREATMENT OF HEPATOTOXICITY
Lo Cascio et al. Curcumin as Scaffold for Drug Discovery against Neurodegenerative Diseases. Biomedicines 2021, 9, 173
Pullaiah Pharmacology of Coleus forskohlii and Forskolin
PT1508334E (pt) Extracto solúvel em água a partir de planta do género solanum e o seu processo de preparação, e composição farmacêutica contendo o extracto solúvel em água